Global Testosterone Undecanoate Market Growth 2025-2031
Description
The global Testosterone Undecanoate market size is predicted to grow from US$ 631 million in 2025 to US$ 912 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Testosterone undecanoate, sold under the brand names Nebido, Aveed, and Andriol among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is taken by mouth two to three times per day with food or given by injection into muscle once every 12 weeks or so.
United States market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Testosterone Undecanoate players cover Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Testosterone Undecanoate Industry Forecast” looks at past sales and reviews total world Testosterone Undecanoate sales in 2024, providing a comprehensive analysis by region and market sector of projected Testosterone Undecanoate sales for 2025 through 2031. With Testosterone Undecanoate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Testosterone Undecanoate industry.
This Insight Report provides a comprehensive analysis of the global Testosterone Undecanoate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Testosterone Undecanoate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Testosterone Undecanoate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Testosterone Undecanoate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Testosterone Undecanoate.
This report presents a comprehensive overview, market shares, and growth opportunities of Testosterone Undecanoate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Oral
Segmentation by Application:
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer AG
Endo Pharmaceuticals
Merck Sharp & Dohme
Taro Pharmaceutical
Cipla
Zhejiang Xianju Pharmaceutical
Zhejiang Medicine Co.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Testosterone Undecanoate market?
What factors are driving Testosterone Undecanoate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Testosterone Undecanoate market opportunities vary by end market size?
How does Testosterone Undecanoate break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Testosterone undecanoate, sold under the brand names Nebido, Aveed, and Andriol among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is taken by mouth two to three times per day with food or given by injection into muscle once every 12 weeks or so.
United States market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Testosterone Undecanoate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Testosterone Undecanoate players cover Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Testosterone Undecanoate Industry Forecast” looks at past sales and reviews total world Testosterone Undecanoate sales in 2024, providing a comprehensive analysis by region and market sector of projected Testosterone Undecanoate sales for 2025 through 2031. With Testosterone Undecanoate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Testosterone Undecanoate industry.
This Insight Report provides a comprehensive analysis of the global Testosterone Undecanoate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Testosterone Undecanoate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Testosterone Undecanoate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Testosterone Undecanoate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Testosterone Undecanoate.
This report presents a comprehensive overview, market shares, and growth opportunities of Testosterone Undecanoate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Oral
Segmentation by Application:
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer AG
Endo Pharmaceuticals
Merck Sharp & Dohme
Taro Pharmaceutical
Cipla
Zhejiang Xianju Pharmaceutical
Zhejiang Medicine Co.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Testosterone Undecanoate market?
What factors are driving Testosterone Undecanoate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Testosterone Undecanoate market opportunities vary by end market size?
How does Testosterone Undecanoate break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
87 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Testosterone Undecanoate by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Testosterone Undecanoate by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
